Calidi Biotherapeutics cash flow statement data for the quarter ended Jun 2026. This cash flow statement covers 17 quarters of results from Mar 2022 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Cash Flow Statement | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||||
| Net Income | 1.46M | 4.16M | -5.36M | -7.76M | -6.46M | -12.50M | -2.02M | -8.23M | -7.22M | -5.77M | -5.07M | -4.15M | -5.06M | -5.76M | -5.18M | 0.17M | -4.16M |
| Share-based CompensationStock Comp. | 1.47M | 1.06M | 1.06M | 1.69M | 1.69M | 13.41M | 1.19M | 1.38M | 7.86M | 7.35M | 0.63M | 2.00M | 1.60M | 1.40M | 0.45M | 0.40M | |
| Gains from Investment SecuritiesGains Investment | -2.09M | -4.03M | -0.46M | -0.14M | -0.09M | 1.28M | |||||||||||
| Cash from OperationsCash from Ops. | -0.47M | -0.27M | -8.60M | -3.88M | -3.11M | -5.17M | -13.52M | -5.19M | -3.83M | -5.49M | -4.95M | -5.42M | -7.13M | -4.88M | -4.24M | -5.05M | |
| Depreciation, Depletion & Amortization | |||||||||||||||||
| Amortizatization of IntangiblesAmort. of Intangibles | 0.11M | 0.20M | 0.02M | 0.20M | 0.15M | 0.27M | -0.24M | 0.01M | 0.00M | 0.30M | |||||||
| Depreciation & Amortization (CF)Dep. & Amort. | 0.39M | 0.39M | 0.43M | 0.42M | |||||||||||||
| Change in Working Capital | |||||||||||||||||
| Change in Account PayablesChange Payables | -0.00M | 536.00 | 1.56M | 0.06M | 0.02M | -1.69M | -5.98M | 1.49M | 0.97M | 0.17M | -0.60M | -1.17M | -0.75M | 0.02M | -0.19M | -0.40M | |
| Change in Accured ExpensesChange Accured Exp. | -0.02M | -0.01M | 2.03M | -0.22M | 0.24M | 1.25M | -0.79M | 0.58M | -0.39M | -0.71M | -0.19M | -0.57M | -1.69M | 0.24M | 0.26M | -0.81M | |
| Investing Activities | |||||||||||||||||
| Capital ExpendituresCapex | 0.16M | 0.25M | 0.19M | 0.07M | 0.07M | 0.01M | 0.01M | 0.01M | 0.01M | 0.06M | 0.03M | 0.03M | |||||
| Cash from Investing ActivitiesCash from Investing | -0.33M | -0.16M | -0.14M | -0.24M | -0.06M | -0.04M | -0.01M | -0.01M | -0.01M | -0.01M | -0.06M | -0.03M | -0.08M | ||||
| Financing Activities | |||||||||||||||||
| Other financing activitiesOther financing | 0.18M | 0.81M | 0.51M | 0.66M | 0.16M | 0.62M | 1.00M | 1.97M | 0.30M | 2.48M | -2.06M | 2.54M | |||||
| Cash from Financing ActivitiesCash from Financing | 7.77M | 4.32M | 3.79M | 6.58M | 21.64M | -2.96M | 3.01M | 5.20M | 6.05M | 13.11M | 8.11M | -0.47M | 9.48M | 0.34M | |||
| Change in Capital Stock | |||||||||||||||||
| Net Shares Issued and RepurchasedNet Shares Issued | 0.62M | 0.04M | 0.23M | 0.01M | 0.22M | ||||||||||||
| Additional items | |||||||||||||||||
| Exchange Rate EffectFX Effect | 0.01M | 0.02M | -0.02M | 0.02M | -0.01M | -0.03M | 0.02M | 0.01M | |||||||||
| Change in Cash | -0.47M | -0.27M | -1.20M | 0.29M | 0.55M | 1.15M | 8.08M | -8.20M | -0.81M | -0.31M | 1.06M | 7.69M | 0.97M | -5.40M | 5.21M | -4.78M | |
| Free Cash FlowFCF | -0.47M | -0.27M | -8.60M | -4.04M | -3.36M | -5.37M | -13.59M | -5.26M | -3.84M | -5.49M | -4.95M | -5.43M | -7.14M | -4.94M | -4.26M | -5.08M | |
| Net Cash FlowNCF | -0.47M | -0.27M | -1.17M | 0.28M | 0.55M | 1.16M | 8.06M | -8.18M | -0.82M | -0.29M | 1.09M | 7.68M | 0.97M | -5.41M | 5.21M | -4.79M |